73 related articles for article (PubMed ID: 15372209)
1. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer.
Han X; Ma L; Gu J; Wang D; Li J; Lou W; Saiyin H; Fu D
J Pathol; 2021 Mar; 253(3):304-314. PubMed ID: 33159698
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Evaluation Based on Dual-Time
Wang F; Cheng C; Ren S; Wu Z; Wang T; Yang X; Zuo C; Yan Z; Liu Z
J Oncol; 2022; 2022():6528865. PubMed ID: 35874634
[TBL] [Abstract][Full Text] [Related]
3. The Value of
Huang S; Chong H; Sun X; Wu Z; Jia Q; Zhang Y; Lan X
Front Med (Lausanne); 2021; 8():668697. PubMed ID: 34692714
[No Abstract] [Full Text] [Related]
4. Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma.
Chang CC; Cho SF; Chuang YW; Lin CY; Huang YF; Tyan YC
Medicine (Baltimore); 2018 Jan; 97(2):e9513. PubMed ID: 29480842
[TBL] [Abstract][Full Text] [Related]
5. The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.
Moon H; Noh WC; Kim HA; Kim EK; Park KW; Lee SS; Choi JH; Han KW; Byun BH; Lim I; Kim BI; Choi CW; Lim SM
Nucl Med Mol Imaging; 2016 Sep; 50(3):246-54. PubMed ID: 27540429
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.
Povoski SP; Murrey DA; Smith SM; Martin EW; Hall NC
BMC Cancer; 2014 Jun; 14():453. PubMed ID: 24942656
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.
Einersen P; Epelboym I; Winner MD; Leung D; Chabot JA; Allendorf JD
J Gastrointest Surg; 2014 Aug; 18(8):1441-4. PubMed ID: 24928186
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer.
Choi HJ; Kang CM; Lee WJ; Song SY; Cho A; Yun M; Lee JD; Kim JH; Lee JH
Yonsei Med J; 2013 Nov; 54(6):1377-83. PubMed ID: 24142641
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.
Wang Z; Chen JQ; Liu JL; Qin XG; Huang Y
World J Gastroenterol; 2013 Aug; 19(29):4808-17. PubMed ID: 23922481
[TBL] [Abstract][Full Text] [Related]
11. The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.
Chen HH; Lee BF; Su WC; Lai YH; Chen HY; Guo HR; Yao WJ; Chiu NT
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1478-85. PubMed ID: 23744342
[TBL] [Abstract][Full Text] [Related]
12. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.
Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T
Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topkan E; Parlak C; Kotek A; Yapar AF; Pehlivan B
BMC Gastroenterol; 2011 Nov; 11():123. PubMed ID: 22074002
[TBL] [Abstract][Full Text] [Related]
14. PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG.
Autio A; Ujula T; Luoto P; Salomäki S; Jalkanen S; Roivainen A
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1918-25. PubMed ID: 20523988
[TBL] [Abstract][Full Text] [Related]
15. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Choi M; Heilbrun LK; Venkatramanamoorthy R; Lawhorn-Crews JM; Zalupski MM; Shields AF
Am J Clin Oncol; 2010 Jun; 33(3):257-61. PubMed ID: 19806035
[TBL] [Abstract][Full Text] [Related]
16. Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease.
Kuker RA; Mesoloras G; Gulec SA
Int Semin Surg Oncol; 2007 Jul; 4():17. PubMed ID: 17623095
[TBL] [Abstract][Full Text] [Related]
17. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection.
Hatano E; Ikai I; Higashi T; Teramukai S; Torizuka T; Saga T; Fujii H; Shimahara Y
World J Surg; 2006 Sep; 30(9):1736-41. PubMed ID: 16850145
[TBL] [Abstract][Full Text] [Related]
18. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.
Lyshchik A; Higashi T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):389-97. PubMed ID: 15372209
[TBL] [Abstract][Full Text] [Related]
19. 18F-fluoro-2-deoxy-D-glucose retention index as a prognostic parameter in patients with pancreatic cancer.
Xi Y; Guo R; Hu J; Zhang M; Zhang X; Li B
Nucl Med Commun; 2014 Nov; 35(11):1112-8. PubMed ID: 25098308
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
